Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Botulinum toxin treatment of secretory disorders

Identifieur interne : 000A84 ( PascalFrancis/Curation ); précédent : 000A83; suivant : 000A85

Botulinum toxin treatment of secretory disorders

Auteurs : Markus Naumann [Allemagne] ; Wolfgang Jost [Allemagne]

Source :

RBID : Pascal:04-0228841

Descripteurs français

English descriptors

Abstract

Botulinum neurotoxin serotype A (BoNT/A) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that BoNT/A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. There is class I evidence for the efficacy of botulinum toxin in axillary hyperhidrosis and class II evidence for palmar hyperhidrosis and gustatory sweating. BoNT/A has the potential to replace current invasive and surgical techniques and should at least be considered as a viable alternative. The results of pilot studies to treat sialorrhea are encouraging. However, the optimal dose, best mode of application, side effects, and duration of BoNT/A action in this condition remain uncertain. We need further formal clinical trials to evaluate risks and benefits of BoNT/A for palliative treatment in of sialorrhea in Parkinson's disease and in bulbar amyotrophic lateral sclerosis. Based on the few reports published, BoNT/A injections into the lacrimal gland for hyperlacrimation may be an elegant method to treat this sometimes disabling condition. Again, larger studies are needed to evaluate the risks and long-term benefits of this treatment option.
pA  
A01 01  1    @0 0885-3185
A03   1    @0 Mov. disord.
A05       @2 19
A06       @3 SUP8
A08 01  1  ENG  @1 Botulinum toxin treatment of secretory disorders
A09 01  1  ENG  @1 Basic and Therapeutic Aspects of Neurotoxins
A11 01  1    @1 NAUMANN (Markus)
A11 02  1    @1 JOST (Wolfgang)
A12 01  1    @1 BIGALKE (HANS) @9 ed.
A12 02  1    @1 DRESSLER (Dirk) @9 ed.
A12 03  1    @1 JANKOVIC (Joseph) @9 ed.
A14 01      @1 Department of Neurology, University of Würzburg @2 Würzburg @3 DEU @Z 1 aut.
A14 02      @1 Department of Neurology, Deutsche Klinik für Diagnostik @2 Wiesbaden @3 DEU @Z 2 aut.
A15 01      @1 Institute of Toxicology, Medical School of Hannover @2 Hannover @3 DEU @Z 1 aut.
A15 02      @1 Department of Neurology, Rostock University @2 Rostock @3 DEU @Z 2 aut.
A15 03      @1 Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine @2 Houston, Texas @3 USA @Z 3 aut.
A20       @1 137-141
A21       @1 2004
A23 01      @0 ENG
A43 01      @1 INIST @2 20953 @5 354000113591720190
A44       @0 0000 @1 © 2004 INIST-CNRS. All rights reserved.
A45       @0 44 ref.
A47 01  1    @0 04-0228841
A60       @1 P @2 C
A61       @0 A
A64 01  1    @0 Movement disorders
A66 01      @0 USA
C01 01    ENG  @0 Botulinum neurotoxin serotype A (BoNT/A) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that BoNT/A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. There is class I evidence for the efficacy of botulinum toxin in axillary hyperhidrosis and class II evidence for palmar hyperhidrosis and gustatory sweating. BoNT/A has the potential to replace current invasive and surgical techniques and should at least be considered as a viable alternative. The results of pilot studies to treat sialorrhea are encouraging. However, the optimal dose, best mode of application, side effects, and duration of BoNT/A action in this condition remain uncertain. We need further formal clinical trials to evaluate risks and benefits of BoNT/A for palliative treatment in of sialorrhea in Parkinson's disease and in bulbar amyotrophic lateral sclerosis. Based on the few reports published, BoNT/A injections into the lacrimal gland for hyperlacrimation may be an elegant method to treat this sometimes disabling condition. Again, larger studies are needed to evaluate the risks and long-term benefits of this treatment option.
C02 01  X    @0 002B17
C03 01  X  FRE  @0 Système nerveux pathologie @5 01
C03 01  X  ENG  @0 Nervous system diseases @5 01
C03 01  X  SPA  @0 Sistema nervioso patología @5 01
C03 02  X  FRE  @0 Bontoxilysin @2 FE @2 FR @5 02
C03 02  X  ENG  @0 Bontoxilysin @2 FE @2 FR @5 02
C03 02  X  SPA  @0 Bontoxilysin @2 FE @2 FR @5 02
C03 03  X  FRE  @0 Traitement @5 03
C03 03  X  ENG  @0 Treatment @5 03
C03 03  X  SPA  @0 Tratamiento @5 03
C07 01  X  FRE  @0 Metalloendopeptidases @2 FE
C07 01  X  ENG  @0 Metalloendopeptidases @2 FE
C07 01  X  SPA  @0 Metalloendopeptidases @2 FE
C07 02  X  FRE  @0 Peptidases @2 FE
C07 02  X  ENG  @0 Peptidases @2 FE
C07 02  X  SPA  @0 Peptidases @2 FE
C07 03  X  FRE  @0 Hydrolases @2 FE
C07 03  X  ENG  @0 Hydrolases @2 FE
C07 03  X  SPA  @0 Hydrolases @2 FE
C07 04  X  FRE  @0 Enzyme @2 FE
C07 04  X  ENG  @0 Enzyme @2 FE
C07 04  X  SPA  @0 Enzima @2 FE
N21       @1 145
N82       @1 OTO
pR  
A30 01  1  ENG  @1 Toxins 2002. Conference @3 Hannover DEU @4 2002

Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:04-0228841

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Botulinum toxin treatment of secretory disorders</title>
<author>
<name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, University of Würzburg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author>
<name sortKey="Jost, Wolfgang" sort="Jost, Wolfgang" uniqKey="Jost W" first="Wolfgang" last="Jost">Wolfgang Jost</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Neurology, Deutsche Klinik für Diagnostik</s1>
<s2>Wiesbaden</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">04-0228841</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0228841 INIST</idno>
<idno type="RBID">Pascal:04-0228841</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002237</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000A84</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Botulinum toxin treatment of secretory disorders</title>
<author>
<name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, University of Würzburg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author>
<name sortKey="Jost, Wolfgang" sort="Jost, Wolfgang" uniqKey="Jost W" first="Wolfgang" last="Jost">Wolfgang Jost</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Neurology, Deutsche Klinik für Diagnostik</s1>
<s2>Wiesbaden</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Bontoxilysin</term>
<term>Nervous system diseases</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Système nerveux pathologie</term>
<term>Bontoxilysin</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Botulinum neurotoxin serotype A (BoNT/A) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that BoNT/A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. There is class I evidence for the efficacy of botulinum toxin in axillary hyperhidrosis and class II evidence for palmar hyperhidrosis and gustatory sweating. BoNT/A has the potential to replace current invasive and surgical techniques and should at least be considered as a viable alternative. The results of pilot studies to treat sialorrhea are encouraging. However, the optimal dose, best mode of application, side effects, and duration of BoNT/A action in this condition remain uncertain. We need further formal clinical trials to evaluate risks and benefits of BoNT/A for palliative treatment in of sialorrhea in Parkinson's disease and in bulbar amyotrophic lateral sclerosis. Based on the few reports published, BoNT/A injections into the lacrimal gland for hyperlacrimation may be an elegant method to treat this sometimes disabling condition. Again, larger studies are needed to evaluate the risks and long-term benefits of this treatment option.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0885-3185</s0>
</fA01>
<fA03 i2="1">
<s0>Mov. disord.</s0>
</fA03>
<fA05>
<s2>19</s2>
</fA05>
<fA06>
<s3>SUP8</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Botulinum toxin treatment of secretory disorders</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG">
<s1>Basic and Therapeutic Aspects of Neurotoxins</s1>
</fA09>
<fA11 i1="01" i2="1">
<s1>NAUMANN (Markus)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>JOST (Wolfgang)</s1>
</fA11>
<fA12 i1="01" i2="1">
<s1>BIGALKE (HANS)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1">
<s1>DRESSLER (Dirk)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="03" i2="1">
<s1>JANKOVIC (Joseph)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01">
<s1>Department of Neurology, University of Würzburg</s1>
<s2>Würzburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Department of Neurology, Deutsche Klinik für Diagnostik</s1>
<s2>Wiesbaden</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA15 i1="01">
<s1>Institute of Toxicology, Medical School of Hannover</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02">
<s1>Department of Neurology, Rostock University</s1>
<s2>Rostock</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA15 i1="03">
<s1>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA15>
<fA20>
<s1>137-141</s1>
</fA20>
<fA21>
<s1>2004</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>20953</s2>
<s5>354000113591720190</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>44 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>04-0228841</s0>
</fA47>
<fA60>
<s1>P</s1>
<s2>C</s2>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Movement disorders</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Botulinum neurotoxin serotype A (BoNT/A) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that BoNT/A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. There is class I evidence for the efficacy of botulinum toxin in axillary hyperhidrosis and class II evidence for palmar hyperhidrosis and gustatory sweating. BoNT/A has the potential to replace current invasive and surgical techniques and should at least be considered as a viable alternative. The results of pilot studies to treat sialorrhea are encouraging. However, the optimal dose, best mode of application, side effects, and duration of BoNT/A action in this condition remain uncertain. We need further formal clinical trials to evaluate risks and benefits of BoNT/A for palliative treatment in of sialorrhea in Parkinson's disease and in bulbar amyotrophic lateral sclerosis. Based on the few reports published, BoNT/A injections into the lacrimal gland for hyperlacrimation may be an elegant method to treat this sometimes disabling condition. Again, larger studies are needed to evaluate the risks and long-term benefits of this treatment option.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B17</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Traitement</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Treatment</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Tratamiento</s0>
<s5>03</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fN21>
<s1>145</s1>
</fN21>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
<pR>
<fA30 i1="01" i2="1" l="ENG">
<s1>Toxins 2002. Conference</s1>
<s3>Hannover DEU</s3>
<s4>2002</s4>
</fA30>
</pR>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A84 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000A84 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:04-0228841
   |texte=   Botulinum toxin treatment of secretory disorders
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024